Director/PDMR Shareholding

RNS Number : 6100T
GlaxoSmithKline PLC
13 October 2017
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment              

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.  

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.2659

55

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

e)

Date of the transaction

2017-10-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr I W Whyte

b)

Position/status

PCA of Mrs V A Whyte (Company Secretary)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.  

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.2659

407

 

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

  

 

e)

Date of the transaction

2017-10-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs D Connor

b)

Position/status

PCA of Mr R G Connor (President, Global Manufacturing & Supply)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

   

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017.  

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.2659

259

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2017-10-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEXLFFDBFFFBD

Companies

GSK (GSK)
UK 100

Latest directors dealings